

# **Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial**

**(Trial Protocol)**

**Program Number:** ChiCTR200030254

**Investigational Drug:** Favipiravir

**Indication:** COVID-19

**Principal Investigator:** Dr. Xinghuan Wang

**Research Institution:** Zhongnan Hospital of Wuhan University

**Version Number:** 1.1

**Release Date:** 2020.2.22

**Clinical Trial Abstract:**

<b>Title</b>	Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial.
<b>Objective</b>	To compare the efficacy and safety between favipiravir and arbidol for adult patients with COVID-19.
<b>Design</b>	Multicenter, randomized, open-labeled, positive parallel controlled clinical trial.
<b>Outcomes</b>	<p><b>Primary outcome:</b></p> <p>Clinical recovery rate after 7 days of treatment.</p> <p>Clinical recovery: body temperature, respiratory rate, and oxygen saturation SPO2 back to normal and cough relief for more than 72 hours.</p> <p>Normal or remission criteria:</p> <p>Axillary temperature <math>\leq 36.6</math> °C, or oral temperature <math>\leq 37.2</math> °C, or rectal or tympanic temperature <math>\leq 37.8</math> °C; respiratory frequency <math>\leq 24</math> times/min without oxygen inhalation; Oxygen saturation <math>\geq 98\%</math> without oxygen inhalation;</p> <p>Cough: mild or no cough.</p> <p><b>Secondary outcomes:</b></p> <p>(1) All-cause mortality during the trial;</p> <p>(2) The rate of respiratory failure during the trial (defined as SPO2 <math>\leq 90\%</math> or PaO2/FiO2 <math>&lt; 300</math> mmHg without oxygen inhalation, and requiring oxygen therapy or higher respiratory support);</p> <p>(3) The time from randomization to fever reduction (patients with fever at the time of enrollment);</p> <p>(4) The time from randomization to cough relief (patients with moderate or severe cough at the time of enrollment);</p> <p>(5) The time from randomization to dyspnea relief (defined as mild or no dyspnea, suitable for patients with moderate to severe dyspnea upon enrollment);</p> <p>(6) The rate of auxiliary oxygen therapy or noninvasive mechanical ventilation during the trial;</p> <p>(7) After one week of treatment, the negative rate of 2019-nCoV RT PCR test for upper respiratory tract specimens (two negative</p>

	<p>tests);</p> <p>(8) The rate of ICU admission during the trial;</p> <p>(9) Incidence of serious adverse events (SAE) during the trial.</p>
<b>Interventions</b>	<p>Experimental group: routine treatment + famiravir tablets (1600 mg/time on the first day, twice a day; 600 mg/time from the second day to the end of the experiment, twice a day).</p> <p>Control group: routine therapy + abidol (200 mg each time, three times a day, from the first day to the end of the trial).</p> <p>Course of treatment: the recommended course of treatment is 7 days, which can be appropriately extended according to the judgment of researchers if necessary.</p>
<b>Participants</b>	Hospitalized patients with confirmed COVID-19 (ordinary type as main).
<b>Inclusion and exclusion criteria</b>	<p><b>Inclusion criteria:</b></p> <p>(1) Aged 18 years or older;</p> <p>(2) Voluntarily signed informed consent;</p> <p>(3) Hospitalized patients diagnosed as COVID-19.</p> <p><b>Exclusion criteria:</b></p> <p>(1) Allergic to fabiravir or abidol;</p> <p>(2) ALT/AST increased 5 times higher than the upper limit of normal, or with child Pugh C;</p> <p>(3) Critical patients with expected survival time &lt; 48 hours;</p> <p>(4) Pregnancy;</p> <p>(5) HIV positive;</p> <p>(6) Considered unsuitable by researchers.</p>
<b>Sample size</b>	240 cases
<b>Test cycle</b>	2020.2-2020.6

## Directory

1. Background .....	6
2. Purpose.....	6
3. Study design and observation endpoints .....	6
3.1. Research design description .....	6
3.2. Study’s endpoints .....	7
3.2.1. The primary endpoints.....	7
Main efficacy indicator: clinical recovery rate at 7 days of treatment.....	7
3.2.2. The secondary endpoints .....	7
4. Study inclusion and exclusion.....	7
4.1. Subject inclusion criteria: .....	8
4.2. Subject exclusion criteria: .....	8
4.3. Subjects withdraw or terminate the trial:.....	8
5. Investigational drug.....	8
5.1. Drug.....	8
5.2. Usage and dosage .....	9
5.3. Duration of treatment .....	9
6. Experimental procedure .....	9
6.1. Research schedule .....	9
6.1.1. Screening.....	9
6.1.2. Enrollment / baseline.....	11
6.1.3. Final research follow-up.....	14
6.1.4. Exit the follow-up early.....	14
6.2. Combining medications, treatments and procedures .....	14
6.2.1. Drugs, treatments, and procedures that require attention.....	14
6.2.2. Prohibited drugs, treatments and procedures.....	14
6.2.3. Emergency medicines, treatments and procedures .....	15
6.2.4. Access to study medication for subjects after study closure.....	15
7. Security assessment.....	15
7.1. Quality standards for safety parameters .....	15
7.1.1. Definition of adverse event (AE).....	15
7.1.2. Serious adverse events (SAEs).....	16
7.1.3. Definition of unexpected problem (UP) .....	16
7.2. Classification of adverse events .....	16
7.2.1. Assessment of severity .....	16
7.2.2. Definition of causality between the AEs and Favipiravir treatment .....	16
7.2.3. Predictable SAEs.....	17
7.3. Duration and frequency of event assessment and follow-up .....	18
7.4. Reporting procedures .....	18
7.4.1. Adverse event reporting.....	18
7.4.2. Reporting of SAEs.....	19
7.4.3. Suspected unexpected serious adverse reactions (SUSARs) .....	20
7.5. Study termination rules .....	21

---

7.6. Security inspection .....	21
8. Statistical analysis plan .....	21
8.1. Statistics and analysis method .....	21
8.2. The analysis data set.....	22
8.3. Sample size.....	22
8.4. Randomization .....	23
9. Management and access of source files.....	23
10. Quality assurance and control .....	23
10.1 Research materials.....	23
10.2. Enablement.....	23
10.3 Monitoring during the study.....	24
10.4. Research center close .....	24
11. Ethics / human subject protection.....	24
11.1. Ethical standards.....	24
11.2. Review and approval of the ethics committee .....	25
11.3. Informed consent of patients .....	25
11.4. Subject and data confidentiality.....	27
11.4.1. Storage of human samples, specimens or data used in research .....	28
12. Data processing and record keeping.....	28
12.1. Responsibility for data collection and management .....	28
12.2. Research data recording .....	28
12.3. Plan deviation.....	29
12.4. Publishing and data sharing policies .....	29
13. Conflict of Interest Policy .....	30

## **1. Background**

The novel coronavirus infection is an important cause of public health emergencies at home and abroad, seriously affecting people's health and social stability. The outbreak of SARS-COV in China in 2003 caused serious social impact. Since the Middle East respiratory syndrome coronavirus (MERS-COV) infection was first reported in 2012, the WHO has received notification of 2,468 laboratory-confirmed MERS-COV infections from 27 countries, with at least 851 reported deaths (case fatality rate 34.5%). Since December 2019, Wuhan city in Hubei province has become the center of the novel coronavirus pneumonia outbreak, attracting widespread attention at home and abroad.

By February 17, 2020, a total of 42,752 cases of COVID-19 infection had been confirmed in Wuhan, and no specific antiviral therapy at present. COVID-19 is prevalent in large numbers of people, and it is of great significance to study the treatment of patients with common type, shorten the course of mild disease and reduce infectivity.

The novel coronavirus is similar to severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which are caused by coronavirus infection, in the preclinical research center, Favipiravir have been shown to inhibit coronavirus with better safety and tolerance. This randomized, parallel-controlled study will assess the efficacy and safety of Favipiravir in hospitalized patients with COVID-19 infection who are predominantly with common type COVID-19.

## **2. Purpose**

To evaluate the efficacy and safety of Favipiravir in the treatment of common type COVID-19 adults.

## **3. Study design and observation endpoints**

### **3.1. Research design description**

This study was a randomized, open-labeled, positive parallel-controlled clinical trial.

Objective to explore the clinical efficacy and safety of Favipiravir in the treatment of adult patients with common type of novel coronavirus pneumonia.

### **3.2. Study's endpoints**

#### **3.2.1. The primary endpoints**

Main efficacy indicator: clinical recovery rate at 7 days of treatment.

Clinical recovery: after treatment, the patient's body temperature, respiratory rate, oxygen saturation back to normal and cough relief for more than 72 hours.

Normal or remission criteria: axillary temperature  $\leq 36.6^{\circ}\text{C}$ , or oral temperature  $\leq 37.2^{\circ}\text{C}$ , or rectal or tympanic temperature  $\leq 37.8^{\circ}\text{C}$ ; respiratory rate  $\leq 24$  times/min without oxygen inhalation; oxygen saturation  $\geq 98\%$  without oxygen inhalation; mild or no cough.

#### **3.2.2. The secondary endpoints**

- (1) All-cause mortality during the trial;
- (2) Incidence of respiratory failure during the experiment (defined as  $\text{SPO}_2 \leq 90\%$  or  $\text{PaO}_2/\text{FiO}_2 < 300$  mmHg without oxygen inhalation and requiring oxygen therapy or higher respiratory support);
- (3) Fever reduction time after randomization (patients with fever at enrollment);
- (4) Time to cough remission after randomization (patients with moderate to severe cough at enrollment);
- (5) Duration of dyspnea relief after randomization (defined as mild or no dyspnea, suitable for patients with moderate to severe dyspnea at enrollment);
- (6) Rate of auxiliary oxygen therapy or non-invasive mechanical ventilation during the test;
- (7) Negative time of 2019-nCoV RT-PCR in upper respiratory tract specimens one week after treatment;
- (8) ICU occupancy rate during the experiments
- (9) Incidence of SAE during the trial.

### **4. Study inclusion and exclusion**

**4.1. Subject inclusion criteria:**

- (1) Patients over 18 years old;
- (2) Voluntarily signed informed consent;
- (3) Hospitalized patients diagnosed with novel coronavirus pneumonia.

**4.2. Subject exclusion criteria:**

- (1) Allergic to Favipiravir or Arbidol;
- (2) ALT/AST increased by 5 times above the normal limit, or child-pugh level C;
- (3) Critically ill patients with an expected survival time < 48 hours;
- (4) Pregnancy;
- (5) HIV positive;
- (6) Considered unsuitable by researchers.

**4.3. Subjects withdraw or terminate the trial:**

Consider discontinuing the study intervention if the patient meets one of the following criteria:

- (1) The patient met discharge standards (two consecutive negative respiratory nucleic acid tests, one day between);
- (2) The patient died;
- (3) An adverse reaction that cannot be tolerated;
- (4) The patient withdraws informed consent;
- (5) Based on the safety and benefit considerations of the subjects, the researchers concluded that it was inappropriate to continue using the study drug.

**5. Investigational drug****5.1. Drug**

This study adopted a positive parallel-controlled design based on conventional treatment. The experimental group was a combination of conventional treatment with Favipiravir tablets, and the control group was a combination of conventional treatment with Arbidol.



## 5.2. Usage and dosage

Subjects will be randomly assigned to one of the following treatment groups.

Group	Plan
Experimental	Routine treatment + Favipiravir tablets (1 day, 1600 mg each time, 2 times daily; From the second day to the end of the test, 600 mg each time, twice a day); Course of treatment: 7-10 days, with appropriate extension at the discretion of the investigator if necessary.
control	Routine treatment + Arbidol; Course of treatment: 7 days, with appropriate extension at the discretion of the investigator if necessary.

## 5.3. Duration of treatment

Recommended course of treatment: 7 days, extended if necessary at the discretion of the investigator.

## 6. Experimental procedure

### 6.1. Research schedule

#### 6.1.1. Screening

Screening criteria: See the diagnostic criteria of the Novel Coronavirus Infected Pneumonia (Sixth Edition):

#### (A) Suspected cases:

Comprehensive analysis of the following epidemiological history and clinical features:

(a) History of epidemiology:

(1) Travel history or residence history of Wuhan and surrounding areas or other communities with case reports within 14 days before the onset.

(2) History of contact with novel coronavirus infection patients (positive for nucleic

acid detection) within 14 days before the onset.

(3) History of contact with novel coronavirus infection patients (positive for nucleic acid detection) within 14 days before the onset.

(4) Clustering disease.

(b) Clinical features:

(1) Fever and/or respiratory symptoms;

(2) With the imaging characteristics of the above-mentioned novel coronavirus pneumonia;

(3) The total number of white blood cells in the early stage of disease is normal or decreased, and the lymphocyte count is reduced.

Have any one of the epidemiological histories and meet any two of the clinical features. If there is no clear epidemiologist, it should meet 3 of the clinical features.

**(B) Confirmed cases:**

Suspected cases with one of the following pathogenic evidence:

(a) Novel coronavirus nucleic acid test positive by qRT-PCR.

(b) The results of viral gene sequencing are highly homologous to known novel coronaviruses.

**Clinical types:**

**(1) Mild type:**

The clinical symptoms are mild and no pneumonia on imaging.

**(2) Moderate type:**

With fever, respiratory tract and other symptoms, imaging shows pneumonia.

**(3) Severe type:**

Meet any of the following:

(a) Shortness of breath, RR > 30 times/minute;

(b) Finger oxygen saturation is < 93% at rest;

(c) Arterial blood oxygen partial pressure (PaO<sub>2</sub>)/oxygen concentration (FiO<sub>2</sub>) <

300mmHg (1 mmHg = 0.133 kPa).

At high altitudes (above 1000 meters), PaO<sub>2</sub>/FiO<sub>2</sub> should be corrected according to the following formula: PaO<sub>2</sub>/FiO<sub>2</sub> X [Atmospheric pressure (mmHg)/760].

Pulmonary imaging shows significant progression of lesions within 24-48 hours> 50% of patients were managed as severe.

**(4) Critical type:**

One of the following:

(a) Respiratory failure and requires mechanical ventilation.

(b) Shock.

(c) Combining other organ failures requires ICU monitoring and treatment.

Clinicians conduct prospective screening of patients daily based on screening criteria. Patients who meet the screening criteria for respiratory pathogenic coronavirus PCR or serum antibody testing. Each principal investigator (PI) must keep a screening log to obtain novel coronavirus test results. As long as influenza-infected patients who meet the inclusion criteria but do not meet any of the exclusion criteria must be recorded in the screening log and filled by the researcher or designated person. If recruit patients meet the inclusion criteria but do not meet any of the exclusion criteria must also record the reasons for not entering the trial in the screening log.

Screening failure was defined as subjects signing informed consent to participate in the study, but withdrawing before the subsequent randomization process. The following information needs to be recorded in the CRF form: the date of informed consent, information about the basic status of the patient, Details of inclusion and exclusion criteria, the reason for the screening failure, and any adverse and serious adverse events that may cause the screening failure.

**6.1.2. Enrollment / baseline**

Once the inclusion and exclusion criteria are confirmed, randomization should be performed as soon as possible (12 hours). According to the recorded inclusion criteria, the maximum acceptable time is 24 hours.

**Demographics:**

The following information should be obtained and recorded from the subject or related person: (age, gender, height, weight, race, and ethnicity).

**Baseline evaluation.**

History of present illness.

Current symptoms: fever, dizziness, headache, fatigue, myalgia, sore throat, cough, expectoration, chest pain, dyspnea, vomiting, diarrhea, abdominal pain, etc.

**Past history:**

Basic respiratory diseases, cardiovascular diseases, chronic liver diseases, immunosuppression, etc.

**Clinical indicators:**

(1) Clinical symptoms and signs: vital signs such as temperature, respiratory symptoms, and other system symptoms.

(2) Related oxygenation indicators: finger pulse oxygen saturation and/or blood gas analysis, respiratory support parameters, oxygen flow/concentration, etc.

(3) Auxiliary inspection: chest CT film, electrocardiogram.

**Laboratory inspection:**

Blood routine, urine routine, blood biochemistry (ALT, AST, GGT, ALP, TBI, CR, BUN, blood glucose, TC, TG, LDL, HDL, CK, CKMB, MAS, lipase), inflammatory indicators (C reactive protein, ESR, etc.).

**Observation items and detection time**

Items	Screening period*	D1-D7 during hospitalization	30 days after discharge

History of illness	√		
HBsAg, HCVAb, HIVAb	√		
Urinary HCG (females of childbearing age)	√		
Combined medication and non-drug therapy	√	Daily record	
Physical examination	√	Daily record	
Vital signs (including body temperature)	√	Daily record	
Respiratory symptoms and signs	√	Daily record	
Finger pulse oxygen saturation/ blood gas analysis	√	Daily record	
Blood routine	√	Test on D3±1、D7±2	
Urine routine	√	Test on D3±1、D7±2	
Blood biochemistry	√	Test on D3±1、D7±2	
CRP	√	Test on D3±1、D7±2	
IL-6	√	(Conditional testing) Test on D3±1、D7±2	
ESR	√	Test on D3±1、D7±2	
Chest CT	√	Test on D7±2	√
12-Lead ECG	√	Test once before discharge	
2019-nCoV-RNA	√	Test on D3±1、D7±2	
Adverse event	√	Daily record	
*Note: The inspection results are valid within 7 days (including 7 days) before signing the informed consent			

### **6.1.3. Final research follow-up**

The longest observation time for each study endpoint in this study was 14 days after enrollment. Every effort should be made to ensure the timely completion of this study follow-up. For discharged patients, a final evaluation is performed by phone.

### **6.1.4. Exit the follow-up early**

- (1) Patient death.
- (2) Patients lost to follow-up.
- (3) Intolerable adverse reactions.
- (4) Patient withdraws informed.
- (5) Based on the safety and benefit considerations of the subject, the investigator consider that it is not appropriate to continue using the study drug.

## **6.2. Combining medications, treatments and procedures**

The attending doctor may decide to support treatment and concomitant treatment according to the Novel Coronavirus Infected Pneumonia (Sixth Edition), as appropriate. Such as: antibacterial drugs, non-steroidal anti-inflammatory analgesics.

### **6.2.1. Drugs, treatments, and procedures that require attention**

In the current situation of novel coronavirus outbreaks, favipiravir has been approved by the State Food and Drug Administration and can be used for this study. Exclusion criteria ensure that patients who are likely to have drug-related adverse reactions are excluded. Favipiravir will be monitored in patients for known side effects. In this study, possible cross-drug interactions will also be detected.

### **6.2.2. Prohibited drugs, treatments and procedures**

- (1) Combination with non-steroidal anti-inflammatory drugs should be avoided as

much as possible. If the subject has severe symptoms such as fever (axillary temperature exceeds 38.5 °C), non-steroidal anti-inflammatory drugs or physical cooling measures can be used as appropriate but must be recorded in detail. Observation of patients with normal body temperature should be performed without the use of antipyretic or measures.

(2) Avoid using hormones in patients with mild-to-moderate disease according to the diagnosis and treatment plan, unless the patient requests or other indications.

### **6.2.3. Emergency medicines, treatments and procedures**

If the patient has severe respiratory failure or exacerbations during the 7-day course of treatment, the use of emergency medication, ventilator, etc. should be performed according to relevant guidelines.

### **6.2.4. Access to study medication for subjects after study closure**

After completing the 7-10 days course, the subjects will no longer receive the drugs provided by this study.

## **7. Security assessment**

### **7.1. Quality standards for safety parameters**

#### **7.1.1. Definition of adverse event (AE)**

AE is defined as any untoward medical occurrence in a patient after administration of Favipiravir treatment that does not necessarily have a causal relationship with this treatment. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with Favipiravir treatment, whether or not related to the Favipiravir treatment.

### **7.1.2. Serious adverse events (SAEs)**

A SAE is any adverse experience occurring during or after Favipiravir treatment that results in any of the following outcomes: death, life-threatening experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or an important medical event.

### **7.1.3. Definition of unexpected problem (UP)**

Unexpected problems are any unexpected events, events, experiences or outcomes in nature, severity or frequency related to the research risks described in the IRB-approved research protocols and informed consent documents; Investigator's handbook or other research documents; Population characteristics of subjects being studied (influenza-infected patients); May, likely or certainly be associated with participation in the study; The risk of harm to subjects or others is greater than previously known or recognized risks (including physical, psychological, economic, or social harm).

## **7.2. Classification of adverse events**

### **7.2.1. Assessment of severity**

The severity of each AE can be assessed using common terminology criteria for adverse events (AIDS version 1.0, December 2004) (clarification date: August 20). The severity of AEs can be assessed by the primary investigators or authorizers according to the following levels:

1 = mild 2 = moderate 3 = severe 4 = life threatening 5 = death.

### **7.2.2. Definition of causality between the AEs and Favipiravir treatment**

The relationship between the AEs and Favipiravir treatment were categorized into five types: definitely unrelated, possibly unrelated, possibly related, very likely to be relevant, highly relevant and to Favipiravir treatment.

Definitely unrelated: An event that can be determined with certainty to have no relationship to the investigational drug, but to other factors such as primary disease,



complications, or other drug administration.

Possibly unrelated: There is no clear relationship with the investigational drug and it may be related to other factors, such as primary illness, complications, or other drug administration.

Possibly related: An adverse event is clearly related to the investigational drug, highly suspected to be related to the investigational drug, but cannot be excluded from the relationship with other factors (such as primary disease, complications, or other drug administrations).

Very likely to be relevant: Clearly related to the investigational drug and can exclude relationships with other factors, such as primary disease, complications, or other drug administration.

Highly relevant: It is clearly related to the investigational drug, which can exclude the relationship with other factors (such as the original disease, complications or other drug administration), and the adverse event occurs again after re-use of the investigational drug.

The last three events should be treated as adverse reactions related to the investigational drug.

### 7.2.3. Predictable SAEs

The principal investigator or authorizer needs to determine whether each SAE is expected or unexpected, regardless of whether the SAE is related to the research operation. The SAEs listed in the table below are expected SAEs.

**Table 1. Expected severe adverse events.**

Coinfection (Including bacteria and fungi, pathogens culled from specimens sent within 48 hours of admission)
secondary infection (over 48 hours)
Acute respiratory distress syndrome
Septic shock
Acute kidney injury
Acute myocardial infarction
Acute heart failure

Disturbance of water-electrolyte acid-base balance
Acute pulmonary embolism
Acute liver injury
Viral myocarditis
Rhabdomyolysis
Invasive complications related to intensive care (catheter-related bloodstream infections, etc.)

#### Unexpected SAE

If a fatal or life-threatening SAE is not listed in Table 2, it is an unexpected SAE.

### 7.3. Duration and frequency of event assessment and follow-up

From the patient's consent to participate in the study to the end of follow-up, the investigator or authorized person is responsible for discovering, recording, and reporting events that meet the definition of AE or SAE.

All SAEs must be followed up until resolution. If SAE has not subsided by the time the initial report is submitted, the PI or other authorized investigator must provide a SAE follow-up report.

SAE will be acquired during the same time period as the AE described above. However, any SAE that was assessed to be related to participation in the study or related to a co-administered drug. All SAEs will be reported within 24 hours.

### 7.4. Reporting procedures

#### 7.4.1. Adverse event reporting

All information on AEs, whether they are mentioned by the subject, discovered by the experimenter, or discovered through physical examination, laboratory tests, and other methods, should be recorded on the adverse event page of the case report form. During the trial, it is necessary to carefully observe and record the occurrence time, duration, symptoms and signs, severity of the adverse events, measures taken, outcomes and evaluation of the relationship with the investigational drug, and follow-up. Those who have abnormal laboratory results at the end of the medication and have clinical intentions need to review this indicator and give appropriate intervention, and follow-up until return to baseline level. Definition of abnormal laboratory results is clinically significant: the subject is normal before the test, if the

value after the test exceeds the upper or lower limit of 150% of the normal value; or before the test, the value after the test is higher or lower than the abnormal value before the test 200%. Or the tester thinks that it is clinically significant. The results of abnormal laboratory tests (such as blood routine and blood biochemistry), which are judged to be clinically significant by the investigator and have little to do with disease progression, should be recorded as AE or SAE. However, any clinically meaningful safety assessment related to the underlying disease will not be reported as AE or SAE unless the investigator determines that the subject is more severe than expected. Expected SAEs are listed in Section 7.2. All other AEs that occur during enrollment and follow-up must be recorded in the patient medical record and eCRF. Information must be recorded on the date of the event, its severity, and the relevance of the trial treatment (as defined above).

The minimum information reported by the SAE will include:

- (1) Patient initials and study number.
- (2) Event nature.
- (3) Event start and end.
- (4) The primary or co-investigator's determination of the relationship between the study drug and the event (probably, likely, or definitely relevant).
- (5) Whether the event requires treatment and what treatment is given.

#### **7.4.2. Reporting of SAEs**

All serious adverse events occurred during the trial are reported within 24 hours from the date of discovery or knowledge. This time requirement also applies to new information (follow-up reports) on SAE reports issued before. The researcher or the person responsible according to the local requirements shall comply with the local regulatory requirements related to the reporting of serious adverse events and report serious adverse events to the regulatory agency and institutional ethics committee. The investigator must complete a SAE report form, detail the occurrence time, severity criteria, duration, relationship with the test drug, measures taken, outcomes, etc., and sign the report. Follow-up information should be reported in a timely manner. The first report should include, to the extent possible: the source of the report, the

basic patient information, the name of the test drug, the name of the SAE, the duration, the severity criteria, the relevance to the investigational drug, the treatment, and the outcome of the event.

**Table 2. SAE reporting units and correspondence addresses.**

Reporting unit	Contact number	Fax	Contacts
Medical Ethics Committee of Zhongnan Hospital of Wuhan University	+86-27-6781278 7	+86-27-678127 87	Dr. Lei Zheng
Department of Science and Education of Hubei Provincial Health Committee	+86-27-8711160 4	---	Dr. Hui Li
Registration Office of Hubei Food and Drug Administration	+86-27-8711169 5	027-87111695	Register
National Drug Administration	+86-10-6831334 4	010-88363228	Registration Division
Division of Evaluation, Science and Education Department, National Health and Health Commission	+86-10-6879220 1	010-68792734	Dr. Bing Chen

#### **7.4.3. Suspected unexpected serious adverse reactions (SUSARs)**

An unexpected AE is any adverse event whose specificity or severity is inconsistent with the investigator's manual or instructions. In addition, the addition of reports of important information about known proven specificity or severity of AEs constitutes unexpected AEs. For example, events that are more specific or severe than those described in the investigator's manual are considered "unexpected" events. As soon as a researcher becomes aware of a SAE, they should immediately conduct a comprehensive analysis, evaluation, and judgment of the SAE. Quickly report to the responsible unit based on the nature (category) of SAEs.

After the first report, the investigator should continue to track serious adverse reactions, and timely report new information or changes to the previous report in the form of a follow-up report. The reporting period is 15 days from the date of obtaining the new information.

### **7.5. Study termination rules**

Trial termination means that the clinical trial has not ended as planned, and all trials are stopped halfway. The main purpose is to protect the rights of the subjects and ensure the quality of the trial. Under the following circumstances, this study may be terminated at any time by Zhongnan Hospital of Wuhan University or the National Drug Administration (NMPA). Reasons for terminating the study may include, but are not limited to, the following:

- (1) The incidence or severity of AEs in this or other studies indicates potential harm to patients.
- (2) Patient enrollment is not ideal.

### **7.6. Security inspection**

This study was monitored by the project team and GCP center for adverse events, and SAE was evaluated and handled.

## **8. Statistical analysis plan**

### **8.1. Statistics and analysis method**

Quantitative variables were described using mean, standard deviation, median, minimum, and maximum values. Categorical variables were described by frequency or composition (%).

Quantitative indicators were compared using group t-test or Wilcoxon's rank-sum test.  $\chi^2$  test or exact probability method was used for categorical variables, and Wilcoxon's rank-sum test or CMH  $\chi^2$  test was used for grade variables.

A two-sided P value of less than 0.05 was considered to indicate statistical significance in all analyses.

The main efficacy indicators (clinical recovery rate after 7 days) was used to compare

of superiority between the experimental group and the control group. The bilateral 95% CI of the difference between the clinical recovery rate of the experimental group and the control group was calculated. If the lower limit was  $> 0$ , the experimental group is considered to be better than the control group.

Log-rank test was employed for the comparison between groups according to time. For the secondary efficacy indicators and safety indicators, t-test or Wilcoxon's rank-sum test (if t-test was not applicable) was used for quantitative indicators,  $\chi^2$  test or exact probability method was used for categorical variables, and Wilcoxon's rank-sum test was used for grade variables.

Adverse events and adverse reactions were listed in the table. The normal or abnormal changes in laboratory indicators before and after treatment and their relationship with study drugs were statistical described.

## **8.2. The analysis data set**

Full Analysis Set (FAS): Based on the Intention-To-Treat (ITT) principle, all randomized subjects were received at least 1 study medication. Meanwhile, randomized subjects who violate inclusion and exclusion criteria, not receive treatment with the study medication, or have no observation data after randomization were excluded. FAS is the main data set for efficacy evaluation. The lack of primary efficacy indicators was filled using principles that were not conducive to the experimental group. The absence of secondary efficacy indicators and safety indicators were not filled.

Per Protocol Set (PPS): It was a subset of FAS and a secondary analysis set for efficacy evaluation. Compared with FAS, subjects who have severely deviated from the protocol that may affect the efficacy evaluation were excluded in PPS.

Safety Set (SS): includes all subjects who received at least 1 study medication.

## **8.3. Sample size**

A total of 240 case were randomly divided into experimental group and control group

with 120 cases in each group.

#### **8.4. Randomization**

In this study, the statistical software SAS9.4 was used to generate a random grouping table to divide the subjects the experimental group and the control group in a 1: 1 distribution ratio. The specific random process was as follows: after confirming that the subjects provide informed consent, and meet all the inclusion criteria and does not meet any of the exclusion criteria, the pre-generated randomization table was used to obtain the subject's random number and drug allocation information.

#### **9. Management and access of source files**

The data for this study were collected using the unified CRF table and established a database. Databases and other research sources were managed according to standards.

#### **10. Quality assurance and control**

This study will be conducted strictly according to the regulations of each research center and GCP guidelines.

##### **10.1 Research materials**

The research center will retain the basic documents required by the GCP guidelines.

##### **10.2. Enablement**

Before the study is initiated, an initial visit will be conducted to ensure that all relevant basic documents and test supplies are in place, and to ensure that participants involved in the study fully understand the study protocol and SOP. All researchers will be trained to explain research protocols and processes.

### **10.3 Monitoring during the study**

The investigator and the head of the medical institution (if applicable) agree to allow the inspector direct access to all relevant documents. The project team and GCP personnel will be responsible for the test audit. On-site inspection visits will be conducted according to the research plan. Auditors will visit the research center several times during the recruitment phase.

During on-site monitoring visits during the study, the study monitor will confirm subject informed consent, check the integrity of data records, data quality, protocol, SOP and GCP compliance, and patient recruitment, study drug storage and follow-up Completion. Audit to ensure:

- (a) Fully obtain the subject's informed consent.
- (b) The safety and rights of the subjects are protected. The study was conducted in accordance with the protocol, GCP guidelines, and applicable regulatory requirements.
- (c) The data is true, accurate and complete.
- (d) In addition, audits may be conducted during or after the study.

### **10.4. Research center close**

After the study is completed, the inspectors will ensure a plan that requires the research center to store relevant data and source files for a long period of time (for 5 years). Study drugs will be checked and destroyed in accordance with local standard procedures.

## **11. Ethics / human subject protection**

### **11.1. Ethical standards**

The research will be carried out strictly according to the relevant ethical principles in the Helsinki Declaration. The research protocol will be reviewed and approved by the research center's Ethics Committee.



### **11.2. Review and approval of the ethics committee**

Researchers and funders should obtain approval from the ethics committee before conducting clinical trials. Researchers and funders should obtain approval documents and other relevant materials reviewed by the ethics committee, including: the name and address of the ethics committee; members of the ethics committee participating in the project review; a statement that the review process meets the requirements of basic norms and relevant laws and regulations; The committee approves the clinical trial and lists the documents reviewed, such as the latest clinical trial protocol, the patient's written informed consent, written documents provided to the patient, patient selection procedures, relevant documents on how to pay the patient's compensation, and ethics committee review Other documents needed. If the review opinion of the ethics committee is “approved after necessary amendments”, such as modifying the protocol, informed consent, and providing the patient and / or other relevant documents, the funder should consult with the researcher and the medical institution where he works to modify Relevant documents are submitted to the ethics committee. If the review opinion of the ethics committee is "disapproval", the funder and the investigator shall modify the issues related to the clinical trial and submit it to the ethics committee for review.

### **11.3. Informed consent of patients**

(1) In the process of patient informed consent, the researcher must comply with the regulatory requirements of the drug regulatory authority and the ethical principles of this specification and the Helsinki Declaration. Researchers should not begin clinical trials until informed consent and other information provided to the patient are approved by the ethics committee.

(2) During the clinical trial, when the investigator obtains new information that may affect the patient's continued participation in the trial, he or she should inform the patient or his legal representative in written form such as informed consent. All

relevant new information needs to be notified to the patient, and the patient should sign the informed consent again after being approved by the ethics committee. Newly enrolled patients should sign updated informed consent forms and other written information.

(3) The investigator or any other researcher shall not use improper means such as coercion and inducement to influence patients to participate in or continue to participate in clinical trials.

(4) Any written or oral information related to the trial must not be in any language that causes patients and their legal agents to waive their legitimate rights and interests, nor can it contain medical institutions, funders, and their agencies serving researchers and their staff Exempt them from responsible language.

(5) The investigator or designated researcher should fully inform the patient of all relevant issues related to the clinical trial, including written information and approval of the ethics committee. Patients who are unable to express informed consent should have their legal representative implement informed consent on their behalf.

(6) The oral and written information provided to the patient, such as the informed consent, should be in plain language and expressions to make it easier for the patient or his legal representative or witness to understand.

(7) Before signing the informed consent, the researcher or designated researcher should give the patient or his legal representative sufficient time and opportunity to understand the details of the trial, and answer all the trial-related information provided by the patient or his legal representative in detail. problem.

(8) The patient or his legal representative, and the investigator performing the informed consent, shall sign and date the informed consent.

(9) During the informed consent process, if the patient or his legal representative lacks reading ability, a fair witness must assist and witness the informed consent. The investigator should explain the content of the informed consent and other written materials to the patient or his legal representative or witness. If the patient or his legal representative agrees to participate in the trial and signs the informed consent, the witness must also sign and date the informed consent to prove that the patient or his

legal representative obtained the informed consent and other written information. The researchers explained accurately, understood the relevant content, and agreed to participate in the clinical trial.

(10) The patient or his legal representative should get a copy of the signed name and date of informed consent and other written information provided to the patient; during the trial, the patient or his legal representative should be updated with the signed name and date. A copy of the informed consent form, as well as revised text of other written materials.

(11) When the legal representative represents the patient's informed consent, he should inform and help the patient to understand the relevant information of the clinical trial as much as possible, and make the patient sign the informed consent and date as much as possible. When a patient participates in a non-therapeutic trial and there is no predictable clinical benefit, the patient must sign and date the informed consent form.

(12) In an emergency, if the patient's informed consent cannot be obtained before participating in the clinical trial, the patient's legal representative must be obtained. If the patient does not have prior informed consent and his legal representative is not present, the patient's selection method should be clearly stated in the clinical trial protocol and/or other documents and obtained written approval from the ethics committee; the patient should also be obtained as soon as possible. Or his legal representative can continue to participate in the informed consent of the clinical trial.

#### **11.4. Subject and data confidentiality**

All records will be kept confidential to the extent required by Chinese law. Research auditors and other authorized agents can review all documents and records kept by the researcher, including but not limited to medical records. Records will remain locked and all computer input and network programs will be done using only coded numbers. No clinical information may be released without the subject's written permission, except as necessary for monitoring by the IRB, CFDA, or the person designated by

the sponsor.

#### **11.4.1. Storage of human samples, specimens or data used in research**

The samples and data collected under this protocol will be used to determine the efficacy and safety of fapilavir, the antiviral effects of virological tests and interventions. The use of stored, unlinked, or unconfirmed samples is exempt from the need for forward-looking IRB review and approval. Applications for exemptions will be submitted in writing and authorized to decide whether to waive research activities.

## **12. Data processing and record keeping**

### **12.1. Responsibility for data collection and management**

This clinical study used an electronic data acquisition (EDC) system for data management. The data management unit is responsible for establishing the database. The data administrator builds a database according to the research plan, and at the same time, performs logical check settings for data validity to check the data. The observation records of each selected case (including shedding cases) must be loaded into the eCRF in a timely, complete, accurate and standardized manner. The completed eCRF must be reviewed and signed (electronically) by the investigator, and data management performed by the clinical trial data manager.

The data administrator checks the data and asks the researcher through the EDC system if the problem is found. The data manager will proofread and modify the data according to the researcher's answer. If necessary, he can send out a question again. After all the questions are resolved, the "clean" data is exported and transferred to the statistical analyst. The main researcher, sponsor, and statistical analyst review and confirm the data, then lock the database, and finalize the statistical analysis plan. The locked data file is no longer changed.

### **12.2. Research data recording**

After the study, the researcher or the head of the medical institution (if applicable) must keep the research records of the research center in a safe place (except as required by local regulations). If required, records must be easily accessible and must be used in conjunction with assessments by agencies, support systems, and related research center staff. To the extent permitted by local laws/regulations or agency policies, some or all records may be kept in hard copy (e.g., microfilm, scanned files, electronic); however, care must be taken before taking such measures. Researchers must ensure that all reproduced documents are legible and that they are true and accurate copies of the original. In addition, if required, accessibility and retrieval criteria must be met, including reconstruction of hard copy copies. Researchers must also ensure that backups are available for the copied files and that there are acceptable quality control procedures for creating copied files. The research center should notify the investigator how long to keep records of the clinical trial facility to meet all applicable regulatory requirements. Based on local laws/regulations and/or institutional requirements, the minimum retention time will meet the strictest standards applicable to a particular research center. The researcher must notify the research center of any changes in the archival arrangement, including but not limited to archiving of records at facilities outside the research center or the transfer of ownership of events in which the researcher is no longer associated with the research center.

### **12.3. Plan deviation**

The number of protocol deviations will be summarized according to the type of deviation (randomization of non-compliant patients, non-compliance with study treatment, and others). All programmed deviations, as well as descriptions and corrective actions taken, will be listed.

### **12.4. Publishing and data sharing policies**

This study will be carried out in the name of a researcher at Zhongnan Hospital of

Wuhan University. The main publication for this study will be the name of the researcher at Zhongnan Hospital of Wuhan University and a full credit will be assigned to all coordinating researchers, research coordinators and institutions. If an individual name is required for publication, the names of the members of the signature supervisory committee and the executive committee, and the name of the main researcher are listed last (corresponding and co-corresponding authors), and then several co-first authors are set up according to the actual contributions of the research.

### **13. Conflict of Interest Policy**

Research subjects can review protocols and assess conflicts of interest.